Viewing Study NCT00502502



Ignite Creation Date: 2024-05-05 @ 6:34 PM
Last Modification Date: 2024-10-26 @ 9:34 AM
Study NCT ID: NCT00502502
Status: COMPLETED
Last Update Posted: 2012-07-20
First Post: 2007-07-16

Brief Title: Assessment of Symptom-Related Cytokines in Lung and Gastrointestinal GI Cancer Patients
Sponsor: MD Anderson Cancer Center
Organization: MD Anderson Cancer Center

Study Overview

Official Title: Feasibility Study of the Assessment of Symptom-Related Cytokines in Lung and GI Cancer Patients Undergoing Chemoradiation Therapy
Status: COMPLETED
Status Verified Date: 2012-07
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Primary Objectives

To determine the feasibility of a study that would describe changes of certain circulating inflammatory cytokines interleukin-1 6 8 10 12 and tumor necrosis factor-alpha TNF and symptoms related to chemoradiation therapy pre-therapy during therapy and up to 3 months post-therapy among patients with lung esophageal gastric colorectal and anal cancer
To determine the feasibility of studying neurocognitive function in patients with non-small cell lung cancer NSCLC at presentation and during chemoradiation therapy to determine the prevalence severity and pattern of cognitive symptoms
Detailed Description: One of the ways to learn about the symptoms of chemoradiation therapy is by looking at how certain proteins called cytokines found in the blood change during therapy Another way is to look at how thinking and memory may be changed because of treatment

Before therapy starts you will be asked to complete several questionnaires during a visit to the Radiation Oncology clinic at M D Anderson These questionnaires measure physical and emotional symptoms These questionnaires should take about 30 minutes to finish Lung cancer patients will also complete some cognitive mental questionnaires During this visit the research nurse will teach you how to use the telephone system for measuring symptoms You will tell the system the most convenient times for the telephone calls The date of the call will be at the same or close to the date of your weekly clinic visit

Before you begin your chemoradiation treatments you will have a sample of blood drawn around 2½ tablespoons The sample of blood will be used to measure levels of cytokines in your blood pre treatment

You will have about 2½ tablespoons of blood drawn again when you start chemoradiation and then once a week while you are receiving treatment These cytokines may be related to symptoms experienced while having treatment for cancer These blood tests are being done to study the levels of cytokines in your blood during and after treatment for cancer

Symptoms will be monitored weekly using an interactive voice response telephone system During chemoradiation the automated telephone system will call you once a week to ask you to rate your symptoms and how much the symptoms interfere in your daily life The information collected by these calls is only being used for this research study

At the end of the chemoradiation lung cancer patients will again be given questionnaires to measure cognitive symptoms

For lung cancer patients who are post-chemotherapy your symptoms will be monitored weekly for 3 months after therapy using the interactive voice response telephone system For esophageal gastric colorectal and anal patients who are post-therapy your symptoms will be monitored weekly for 6 weeks after therapy using the interactive voice response telephone system About 30 days after chemoradiation you will have 2½ tablespoons of blood drawn at your regularly scheduled clinic visit If you are not scheduled for a 3 month clinic visit we will contact your local physician for blood lab results

This is an investigational study About 225 evaluable patients will take part in this study All will be enrolled at M D Anderson

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None